Literature DB >> 11823443

The severe G480C cystic fibrosis mutation, when replicated in the mouse, demonstrates mistrafficking, normal survival and organ-specific bioelectrics.

Paul Dickinson1, Stephen N Smith, Sheila Webb, Fiona M Kilanowski, Isla J Campbell, Martin S Taylor, David J Porteous, Rob Willemsen, Hugo R de Jonge, Ray Farley, Eric W F W Alton, Julia R Dorin.   

Abstract

The majority of cystic fibrosis patients produce a mutant form of CFTR (DeltaF508) which has been shown to be mislocalized in both humans and mice. G480C, another clinically 'severe' mutation, has also been demonstrated to be defective in its intracellular processing, but when allowed to traffic in Xenopus oocytes showed similar channel characteristics to that of wild-type CFTR. We have replicated the G480C mutation in the murine Cftr gene using the 'hit and run' double recombination procedure. As expected, the G480C cystic fibrosis mouse model expresses the G480C mutant transcript at a level comparable to that of wild-type CFTR: The homozygous mutant mice were fertile, had normal survival, weight, tooth colour and no evidence of caecal blockage, despite mild goblet cell hypertrophy in the intestine. Analysis of the mutant protein revealed that the majority of G480C CFTR was abnormally processed and no G480C CFTR-specific immunostaining in the apical membranes of intestinal cells was detected. The bioelectric phenotype of these mice revealed organ-specific electrophysiological effects. In contrast to DeltaF508 'hit and run' homozygotes, the classic defect of forskolin-induced chloride ion transport is not replicated in the caecum, but the response to low chloride in the nose is clearly defective in the G480C mutant animals. The mild phenotype of these G480C mutant animals combined with the defective chloride transport in the nose uniquely provides a valuable resource to test novel pharmacological agents aimed at improving trafficking and correcting the electrophysiological defect in the respiratory tract.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11823443     DOI: 10.1093/hmg/11.3.243

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  12 in total

1.  Cre-mediated germline mosaicism: a new transgenic mouse for the selective removal of residual markers from tri-lox conditional alleles.

Authors:  Patricia Leneuve; Sabine Colnot; Ghislaine Hamard; Fiona Francis; Michiko Niwa-Kawakita; Marco Giovannini; Martin Holzenberger
Journal:  Nucleic Acids Res       Date:  2003-03-01       Impact factor: 16.971

Review 2.  Animal models for cystic fibrosis liver disease (CFLD).

Authors:  Romina Fiorotto; Mariangela Amenduni; Valeria Mariotti; Massimiliano Cadamuro; Luca Fabris; Carlo Spirli; Mario Strazzabosco
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-07-30       Impact factor: 5.187

Review 3.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

4.  Keratin K18 increases cystic fibrosis transmembrane conductance regulator (CFTR) surface expression by binding to its C-terminal hydrophobic patch.

Authors:  Yuanyuan Duan; Ying Sun; Fan Zhang; Wei Kevin Zhang; Dong Wang; Yan Wang; Xu Cao; Wenbao Hu; Changyan Xie; John Cuppoletti; Thomas M Magin; Haixia Wang; Zhenguo Wu; Ning Li; Pingbo Huang
Journal:  J Biol Chem       Date:  2012-10-08       Impact factor: 5.157

Review 5.  The cystic fibrosis of exocrine pancreas.

Authors:  Michael Wilschanski; Ivana Novak
Journal:  Cold Spring Harb Perspect Med       Date:  2013-05-01       Impact factor: 6.915

6.  Inherited neuropathies.

Authors:  Angelo Schenone; Lucilla Nobbio; Margherita Monti Bragadin; Giulia Ursino; Marina Grandis
Journal:  Curr Treat Options Neurol       Date:  2011-04       Impact factor: 3.598

Review 7.  On the Corner of Models and Cure: Gene Editing in Cystic Fibrosis.

Authors:  Marjolein Ensinck; Angélique Mottais; Claire Detry; Teresinha Leal; Marianne S Carlon
Journal:  Front Pharmacol       Date:  2021-04-27       Impact factor: 5.810

8.  Ceramide in cystic fibrosis: a potential new target for therapeutic intervention.

Authors:  Gabriella Wojewodka; Juan B De Sanctis; Danuta Radzioch
Journal:  J Lipids       Date:  2010-12-28

9.  Instability of the insertional mutation in CftrTgH(neoim)Hgu cystic fibrosis mouse model.

Authors:  Nikoletta Charizopoulou; Silke Jansen; Martina Dorsch; Frauke Stanke; Julia R Dorin; Hans-Jürgen Hedrich; Burkhard Tümmler
Journal:  BMC Genet       Date:  2004-04-21       Impact factor: 2.797

10.  Very mild disease phenotype of congenic CftrTgH(neoim)Hgu cystic fibrosis mice.

Authors:  Balázs Tóth; Martina Wilke; Frauke Stanke; Martina Dorsch; Silke Jansen; Dirk Wedekind; Nikoletta Charizopoulou; Alice Bot; Marion Burmester; Sabine Leonhard-Marek; Hugo R de Jonge; Hans-Jürgen Hedrich; Gerhard Breves; Burkhard Tümmler
Journal:  BMC Genet       Date:  2008-04-09       Impact factor: 2.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.